Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr 24;20(8):2004.
doi: 10.3390/ijms20082004.

Biomarkers in Pneumonia-Beyond Procalcitonin

Meropi Karakioulaki  1 , Daiana Stolz  2
Affiliations
Review

Biomarkers in Pneumonia-Beyond Procalcitonin

Meropi Karakioulaki et al. Int J Mol Sci. .

Abstract

Pneumonia is the leading infectious cause of mortality worldwide and one of the most common lower respiratory tract infections that is contributing significantly to the burden of antibiotic consumption. Due to the complexity of its pathophysiology, it is widely accepted that clinical diagnosis and prognosis are inadequate for the accurate assessment of the severity of the disease. The most challenging task for a physician is the risk stratification of patients with community-acquired pneumonia. Herein, early diagnosis is essential in order to reduce hospitalization and mortality. Procalcitonin and C-reactive protein remain the most widely used biomarkers, while interleukin 6 has been of particular interest in the literature. However, none of them appear to be ideal, and the search for novel biomarkers that will most sufficiently predict the severity and treatment response in pneumonia has lately intensified. Although our insight has significantly increased over the last years, a translational approach with the application of genomics, metabolomics, microbiomics, and proteomics is required to better understand the disease. In this review, we discuss this rapidly evolving area and summarize the application of novel biomarkers that appear to be promising for the accurate diagnosis and risk stratification of pneumonia.

Keywords: biomarkers; novel; pneumonia; procalcitonin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Kaziani K., Sotiriou A., Dimopoulos G. Duration of pneumonia therapy and the role of biomarkers. Curr. Opin. Infect. Dis. 2017;30:221–225. doi: 10.1097/QCO.0000000000000351. - DOI - PubMed
    1. Lopardo G.D., Fridman D., Raimondo E., Albornoz H., Lopardo A., Bagnulo H., Goleniuk D., Sanabra M., Stamboulian D. Incidence rate of community-acquired pneumonia in adults: A population-based prospective active surveillance study in three cities in South America. BMJ J. 2018;8:e019439. - PMC - PubMed
    1. Walker C.L.F., Rudan I., Liu L., Nair H., Theodoratou E., Bhutta Z.A., O’Brien K.L., Campbell H., Black R.E. Global burden of childhood pneumonia and diarrhoea. Lancet. 2013;381:1405–1416. doi: 10.1016/S0140-6736(13)60222-6. - DOI - PMC - PubMed
    1. Wunderink R.G., Waterer G.W. Community-acquired pneumonia. N. Engl. J. Med. 2014;370:1863. doi: 10.1056/NEJMcp1214869. - DOI - PubMed
    1. British Thoracic Society Standards of Care Committee BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax. 2001;56:1–64. doi: 10.1136/thx.56.suppl_4.iv1. - DOI - PMC - PubMed

MeSH terms